新华制药：获得恩他卡朋片药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which are prescription drugs that assist in the treatment of Parkinson's disease and end-of-dose wearing-off phenomena, classified as a Category B item in the medical insurance directory [1] Group 1 - The approved drug is expected to generate approximately 286 million yuan in sales for public medical institutions in China in 2024 [1] - This approval enhances the company's formulation product portfolio and improves its overall competitiveness [1] - The sales of the drug may be influenced by policies and market factors, leading to uncertainties [1]